Andrade, M. de O. et al. 2026. Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/ GBECAM-0123 study. Mastology. 35, suppl.1 (Feb. 2026). DOI:https://doi.org/10.29289/259453942025V35S1030.